MetLife (MET), Why Is The Story Getting More Complicated?

MetLife (MET) is back in focus after fresh performance data showed a year-to-date total return of 20.9%. Over the past 3 months, the stock added 11.1%, while performance in the past month was slightly weaker at 0.5% lower.

MetLife’s recent share price performance has been strong over the year, with a 20.9% year-to-date share price return and a 24.2% total shareholder return over 12 months. This points to momentum building rather than fading despite some softer short-term moves.

Scan how MetLife’s momentum compares with other large insurers by reviewing our hand picked list of list of solid balance sheet and fundamentals (23 results) in one place.

MetLife has already delivered strong gains, yet the shares still trade below analyst targets and an estimated intrinsic value. Is most of the upside already in the rear view mirror or is pricing still playing catch up?

Most Popular Narrative: 7% Undervalued

MetLife last closed at $97.14, while the most followed narrative framework pegs fair value at $104.38 based on a 7.52% discount rate. That gap reflects a view that the market is not fully pricing in the business mix shift and capital choices shaping the next phase.

Strategic expansion of asset-light, fee-generating businesses (like employee benefits, asset management, and longevity reinsurance), combined with disciplined capital management, supports higher return on equity and more consistent, less capital-intensive earnings growth.

Early leadership and scale in emerging product and distribution platforms should allow MetLife to secure an outsized share of future profit pools as these markets mature and deepen.

See why 26 investors see MetLife as 7% undervalued.

Result: Fair Value of $104.38 (UNDERVALUED)

Still, the MetLife story can change quickly if commercial mortgage loan credit losses deepen, or if slower digital adoption lets newer platforms pull customers away.

Find out about the key risks to this MetLife narrative.

Another View On MetLife’s Valuation

The earlier narrative framed MetLife as undervalued, with the share price at $97.14 versus a fair value of $104.38. A different lens tells a less generous story. On a P/E of 17.9x, the stock trades well above the US Insurance industry on 11.1x and peers on 14.9x, and also above a fair ratio of 14.5x.

That gap suggests investors are already paying a premium multiple for MetLife compared with both sector norms and where the P/E could converge over time. The question becomes whether the current growth and capital return profile really justifies staying on the expensive side of that range.

For a closer look at how this pricing compares across peers and where valuation pressure might build next, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals in the MetLife story can feel uncomfortable, especially when valuation and sentiment are pulling in different directions. Act while the data is fresh and build your own view using the 3 key rewards and 1 important warning sign.

Ready For More MetLife Investment Ideas?

If you stop at MetLife, you miss the wider opportunity set. Put the current valuation in context by lining it up against other, data driven ideas.

• Target steadier compounding and focus on resilient balance sheets by reviewing our curated 11 resilient stocks with low risk scores built around lower risk profiles.
• Hunt for quality at a discount and compare MetLife with a 32 high quality undervalued stocks that blend solid fundamentals with pricing that has not fully caught up yet.
• Spot potential future leaders early and scan a 15 high quality undiscovered gems that many investors have not yet put on their radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com